Delivery Technology

Nutrient deficiency is at the core of nearly every disease and chronic health condition. First there is the ever declining nutrient richness of foods. Second there is the ever increasing incidence of poor gut absorption due to factors which include poor eating habits, increased stress, toxin/chemical exposure, and epigenetics. Third, there is the ever increasing depletion of nutrients by medications. With the discovery of master neurotransmitter nitric oxide (NO) as the body’s nutrient delivery system, we find nutrient demand and subsequent deficiency goes one step further as nutrients, especially amino acids, are also responsible for producing the actual nutrient delivery mechanism, in the form of neurotransmitters like nitric oxide.

N.P.S.™ (Neurotransmitter Production Support, a proprietary technology protected under major university patents), was an effort to harness the body’s own nutrient delivery system – to  target the same process the body uses to activate NT synthesis, with the goal of significantly increasing NT synthesis using minimal amounts of the individual agents. N.P.S.™ increases NT production by supplying NT precursors and simultaneously promoting neuron firing. For NTs to be produced, certain nerve cells must be activated.  Unless these nerve cells are activated, simply supplying nutrients is insufficient to increase NT production.

To illustrate this concept, imagine a factory.  In order for a factory to convert raw materials into a finished product the assembly line must be turned on.  If the assembly line remains inactive, the raw materials will not be converted into the finished product.  N.P.S.™ therapies are designed to “turn on” cells that change the “raw materials” into NTs.

N.P.S.™ is based upon five elements: (1) bypass gut-intestinal absorption, (2) deliver NO precursors, (3) activate the NT “factory” (4) produce NO signaled vasodilation, and (5) deliver nutrients throughout the body, especially to peripheral and capillary regions where nutrients often do not reach.

Targeting each of the crucial mechanisms needed to activate synthesis of a NT is similar to opening a door with a combination lock.  Without the right combination (in this case nutrient combination), the door will not open. This is why administering large multi-gram quantities of single NT precursors (the bulldozer approach) fails to produce significant increases in NT synthesis.

Unlike drugs, inhibiting or stimulating mechanisms beyond normal range, N.P.S.™ based therapies are designed to only restore under-functioning mechanisms to within the normal range.  This results in therapies having a greater margin of safety as compared to pharmaceuticals. As such our scientists served as protocol advisors on NT studies and collaborate with scientific researchers from major universities, human/vet pharmaceutical groups, dietary supplement manufacturers, anodyne therapy/hyperbaric therapy groups, and health/charitable foundations.